Lifeboat Foundation

Eva Ramón Gallegos, a researcher from Mexico National Polytechnic Institute (IPN) was able to completely eradicate the Human Papilloma Virus (HPV) in 29 patients. This scientific achi…

The six newly shortlisted initiatives include: a project that would explore how AI can enhance human capabilities; one to hasten clinical availability of cell and gene therapies; a personalized-medicine initiative; two projects that aim to make solar energy more efficient; and a humanities project called the Time Machine, which seeks to develop methods for enabling digital search of historical records in European cities.

AI enhancement and a virtual time machine are included in the shortlist of pitches.

GOODBYE, FILLINGS Dental fillings may soon be left in the ash heap of history, thanks to a recent discovery about a drug called Tideglusib. Developed for and trialled to treat Alzheimer’s disease, the drug also happens to promote the natural tooth regrowth mechanism, allowing the tooth to repair cavities.

Patients and doctors have been waiting for this device for decades.

The discovery is the first step in developing a stem cell therapy to help patients recover from bone fractures, spinal fusion, and osteoporosis.

By discovering the culprit behind decreased blood flow in the brain of people with Alzheimer’s, biomedical engineers at Cornell University have made possible promising new therapies for the disease.

You know that dizzy feeling you get when, after lying down for an extended period, you stand up a little too quickly?

That feeling is caused by a sudden reduction of blood flow to the brain, a reduction of around 30 percent. Now imagine living every minute of every day with that level of decreased blood flow.

Continue reading “Researchers closer to new Alzheimer’s therapy with brain blood flow discovery” »

We recently visited the Longevity Leaders Conference in London and had the opportunity to speak with Kelsey Moody, the CEO of Ichor Therapeutics, a company focused on targeting age-related diseases by targeting the aging processes themselves. We previously interviewed him back in 2017, so it was the ideal time to catch up on what had been happening with his company since then.

Ichor and its portfolio companies have been very busy over the last year, so I thought it was time that we caught up on progress. Can you tell us how things are going for the Ichor group?

Ichor really had a good year in 2018. We raised over $16 million across our portfolio, and that’s really allowed us to scale up all aspects of our operations. We’re at over 50 employees now, mostly bench scientists and research technicians, and we’re really delivering on our goal of being a vertically integrated biopharmaceutical company.

Continue reading “An Interview with Kelsey Moody – Developing a Company to End Age-Related Diseases” »

“We found that lactate stimulates synaptic activity-dependent genes in the short-term and genes involved in regulating neuronal excitability in the long-term,” explains the first author of the paper Michael Margineanu, a KAUST Master’s student.

Study illustrates the links between brain energy metabolism and neuronal activity.

A genome-wide study led by Dean Pierre Magistretti sheds light on the mechanisms through which lactate regulates long-term memory formation and neuroprotection.

Continue reading “Lactate activates multiple genes that modulate neuronal activity” »